Show simple item record

Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey

dc.contributor.authorRichardson, M.T.
dc.contributor.authorAttwood, K.
dc.contributor.authorSmith, G.
dc.contributor.authorLiang, S.-Y.
dc.contributor.authorLaVigne, Mager, K.
dc.contributor.authorTewari, K.S.
dc.contributor.authorColeman, R.L.
dc.contributor.authorKapp, D.S.
dc.contributor.authorChan, J.K.
dc.contributor.authorMonk, B.J.
dc.date.accessioned2024-08-04T07:12:19Z
dc.date.available2024-08-04T07:12:19Z
dc.date.issued2023-08-30
dc.identifier.citationRichardson, M. T., Attwood, K., Smith, G., Liang, S. Y., LaVigne Mager, K., Tewari, K. S., ... & Monk, B. J. (2023). Sequential targeted therapy for advanced, metastatic, and recurrent cervical cancer: A cost-effectiveness analysis of the patient journey. Cancer control, 30, 10732748231182795.
dc.identifier.issn1073-2748
dc.identifier.pmid37646470
dc.identifier.doi10.1177/10732748231182795
dc.identifier.urihttp://hdl.handle.net/10150/673596
dc.description.abstractObjectives: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. Method: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-826, and tisotumab vedotin (tiso) from GOG 3023. Costs were based on IBM Micromedex RED BOOK™ and company listed costs. Results: For [chemo + bev → chemo], total cost was $125,918.04, with median overall survival (mOS) of 21.8 months, and cost-effectiveness ratio (CER) of $119,835.79. For [chemo + bev → cemi], total cost was $187,562.99 with mOS of 28.5 months and CER of $162,039.16. For [chemo + bev + pembro → chemo], total cost was $319,963.78 with mOS 32.9 months and CER of $249,930.10. For [chemo + bev + pembro → tiso], total cost was $455,204.45, with mOS 36.5 months and CER of $320,072.99. Conclusion: The combination of immunotherapies and biologics have significantly increased overall survival, but with associated higher costs, primarily related to drug costs. © The Author(s) 2023.
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.rights© The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectcervical cancer
dc.subjectcost-effectiveness
dc.subjectimmunotherapy
dc.subjectnovel therapies
dc.subjectsequential treatments
dc.titleSequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey
dc.typeArticle
dc.typetext
dc.contributor.departmentUniversity of Arizona College of Medicine-Phoenix
dc.contributor.departmentHonor Health Research Institute, University of Arizona
dc.identifier.journalCancer Control
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal Published Version
dc.source.journaltitleCancer Control
refterms.dateFOA2024-08-04T07:12:19Z


Files in this item

Thumbnail
Name:
richardson-et-al-2023.pdf
Size:
591.2Kb
Format:
PDF
Description:
Final Published Version
Download

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.
Except where otherwise noted, this item's license is described as © The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.